| Gene symbol | CLU | Synonyms | AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p21.1 | dbXrefs | |
| Description | clusterin | ||||
| GTO ID | GTC0577 |
| Trial ID | 2012-002447-14 |
| Disease | Lung Non-Small Cell Carcinoma |
| Altered gene | CLU |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-011|custirsen sodium|TV-1011 |
| Phase | Phase3 |
| Recruitment status | Prematurely Ended |
| Title | A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer |
| Year | 2012 |
| Country | Australia|Germany|Hungary|Israel|Italy|Korea,Republic of|New Zealand|Poland|Russian Federation|Singapore|Spain|China|Thailand|Ukraine|United States |
| Company sponsor | OncoGenex Technologies Inc |
| Other ID(s) | NCT01630733 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||